Effectiveness of adjuvant trastuzumab in daily clinical practice

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40–50% and reduces the risk of dying from HER2 positive breast cancer by one th...

Descripción completa

Detalles Bibliográficos
Autores principales: Matos, Erika, Zakotnik, Branko, Kuhar, Cvetka Grasic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230562/
https://www.ncbi.nlm.nih.gov/pubmed/25435855
http://dx.doi.org/10.2478/raon-2013-0081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230562/
https://www.ncbi.nlm.nih.gov/pubmed/25435855
http://dx.doi.org/10.2478/raon-2013-0081

Ejemplares similares